摘要：This meta-analysis aimed to assess the effectiveness of moist exposed burn ointment (MEBO) for diabetic foot ulcers (DFU). Two researchers independently assessed the quality and validity of included randomized controlled trials (RCTs) in 7 electronic databases. Risk of bias was assessed using Cochrane handbook guidelines. Twenty seven trials which include 1,979 patients were involved for analysis. Comparison of the same intervention strategies revealed significant differences in total effectiveness rates between BEBO and conventional therapy group (Risk Ratio [RR], 6.36, [95% confidence interval (CI), 3.20, 12.64], P < 0.00001); MEBO combined with standard therapy (Risk Ratio [RR], 1.19, [95% confidence interval (CI), 1.08, 1.31], P = 0.0007); and healing time of DFU (Mean Difference [MD], 14.15, [95% confidence interval (CI), -18.14, -10.17], P < 0.00001). MEBO may be effective for treating DFU. However, a firm conclusion could not be reached because of the poor quality of the included trials. Further trials with higher quality are justified.   Key words: Exposed wound ointment (MEBO), diabetic foot ulcers (DFU), recombinant bovine, basic fibroblast growth factor (rb-bFGF), vacuum sealing drainage (VSD).

摘要：Following traumatic or surgical injury to the skin, wounds do not heal by tissue regeneration but rather by scar formation. Though healing is definitely a welcomed event, the resultant scar, very often, is not aesthetically pleasing, and not infrequently, may be pathologic causing serious deformities and contractures. Management of problematic scars continues to be a frustrating endeavor with less than optimal results. Prophylactic methods of wound management to minimize serious scarring are being developed. In a previously published study, we have demonstrated improved healing of split thickness skin graft donor sites following treatment with Moist Exposed Burn Ointment (MEBO, Julphar Gulf Pharmaceutical Industries, Ras Al-Khaimah, UAE). At present, we are reporting the results of a comparative clinical prospective study evaluating scar quality following primary healing of elective surgical and traumatic facial wounds with prophylactic MEBO application, topical antibiotic ointment application, and no topical therapy at all. Scars were evaluated according to the Visual Analogue Scale for scar assessment. Statistical analysis of scar assessment scores demonstrated marked prevention of unfavorable scars with improved cosmetic results following MEBO prophylactic therapy.

摘要：The present study aimed to compare between the use of platelet rich fibrin membrane (PRFM) and MEBO scar ointment for cutaneous wound healing as a model treatment. For this reason, forty two local breed rabbits have been divided into four groups, the first three groups were subjected to full thickness skin wound using biopsy punch instrument (diameter 8 mm) on the dorsal thoracic side. Rabbits in the first group leaved without treatment, while in the second group we planted the PRFM in biopsy site, the third group treated with MEBO scarointment. Wound healing process was observed grossly and microscopically at day 3, 7, 10 and 12 post operation.All groups showed normal healing process with competitive advantage to PRFM and MEBO groups respectively compared with untreated group, PRFM was better than the MEBO group, the advantage characterized by less inflammatory reaction, fast reepitheliazation, granulation tissue formation, fibroplasias, and angiogenesis.

摘要：Objective: Many topicals claim an efficacious role in skin scar management with limited evidence. Our aim is to present a clear format for functional testing of a skin scarring ointment, using noninvasive and invasive measurements, categorizing findings under the physiological, structural, and mechanical parameters of a scar., Approach: A double-blinded, randomized volunteer research study of 45 subjects receiving an ointment composing of natural ingredients against a widely used antiscarring topical used as a positive control with temporal sequential punch biopsies (up to 16 weeks) was evaluated using noninvasive quantitative devices and validated by gene and protein studies., Results: Outcome measures included physiological, mechanical, and structural features of scars. Significant non-invasive findings included an increase in skin hydration (p?<?0.05) at week (W) 4, 8, and 12, and elasticity (W16; p?=?0.009). These findings were validated by immunohistochemistry (IHC) and quantitative real-time PCR (qRT-PCR). Hyaluronic acid IHC (W4 p?=?0.014, W12 p?=?0.034, and W16 p?=?0.042), qRT-PCR (W16 p?=?0.049); Collagen I (W16 p?=?0.034, and 0.049) IHC and qRT-PCR, respectively. Collagen III qRT-PCR (W12 p?=?0.035, and W16 p?=?0.32); elastin IHC (W12 p?=?0.044); and fibronectin IHC (W4 p?=?0.009, W12 p?=?0.038, and W16 p = 0.026)., Innovation: Utilizing this model allows for quantitative, objective evaluation of any topical, where previously there has been a paucity of relevant methods to evaluate their effect., Conclusions: The positive effect of a topical formulation with an unknown mechanism of action on early cutaneous scar maturation over progressive sequential time points is now evidenced using noninvasive and invasive techniques with the findings categorized on the basis of scarring parameters.